SR9009

SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.


A new compound called SR9009 increases metabolism, fat burning, and muscle growth in the lab. Scientists at The Scripps Research Institute (TSRI) have successfully tested a drug, called SR9009,in mice that kickstarts metabolism and results in increased muscle development. Essentially, it's an exercise regime in a pill.

SR9009 alters the metabolic profile of skeletal muscle in a manner similar to the changes observed
[in] animals [that] are endurance trained. Basically, the drug sends a signal to the muscle to tell it to modify its metabolism.

Web: *
Web: *
Email: *
Skype: +8615711952876
Whatsapp +8615711952876